Cagent Vascular Initiates Enrollment of PRELUDE-BTK Study Using Serranator Device

By Natalie GoodridgeJanuary 7, 2020October 22nd, 2024Healthcare

No Comments

Cagent Vascular Initiates Enrollment of PRELUDE-BTK Study Using Serranator Device

https://cagentvascular.com/news/prelude-btk

Tags:

Cagent Vascular Healthcare

PreviousTISSIUM Recognized as a French Tech 120 Company
NextFirst Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-Threatening Ischemia

M&L GROUP

We are a family investment firm that cultivates pioneering ventures into successful enterprises with passion, energy and integrity.

Hospitality

Healthcare

Shipping

Alternatives

Media room

About

Contact

Copyright © 2025 M&L Group. All Rights Reserved. | Legal.

Branding and website design by Stepworks